Neurodegeneration CROs: Alzheimer’s, Parkinson’s and ALS Models

8 contract research organizations in our directory list Neurodegenerative Models as a capability, across 4 countries. 1 reports GLP capability and 1 reports AAALAC accreditation. Compare their species, services and accreditations below, and contact labs directly from their profiles.

8 CROs 1 GLP 1 AAALAC 4 countries

About Neurodegenerative Models

Neurodegenerative disease models are some of the longest and most expensive in vivo studies. Alzheimer’s programs use amyloid models such as APP/PS1 and 5xFAD mice and tau models such as P301S lines. Parkinson’s programs use toxin models (MPTP, 6-OHDA) and alpha-synuclein models based on preformed fibril injection or viral overexpression. ALS work commonly uses SOD1 and TDP-43 models, and Huntington’s disease uses lines such as R6/2 and knock-in models.

Endpoints combine behavior and motor function, histopathology and stereology, and fluid biomarkers such as neurofilament light in plasma or CSF. Disease often develops over months, so availability of aged cohorts and colony management are practical constraints, and group sizes must allow for attrition.

Many of these programs use antisense oligonucleotides or gene therapies that must be delivered intrathecally, into the ventricles or into the cisterna magna, which adds surgical skill to the list of things to evaluate. Our team has hands-on experience with these CNS routes.

CNS drug delivery methods →

Showing 8 CROs. Order rotates daily so no lab is permanently listed first.

Biomere

US Verified AAALAC

Biomere (a JOINN company) is a preclinical CRO based in Worcester, MA. Services include non-GLP PK/PD, discovery toxicology, surgical services, disease models, and laboratory sciences. Surgical services include…

Neurodegenerative Models AAV Biodistribution Bioanalysis Bioavailability Studies Biodistribution Cynomolgus monkey Minipig Mouse Non-human Primate

Neuron Experts

FR

French neuroscience CRO offering in vitro and in vivo models for neurological and neurodegenerative drug discovery.

Neurodegenerative Models CNS Disease Models In Vivo Efficacy Mouse Rat

Neuro-Sys

FR

French neuroscience CRO dedicated to in vitro and in vivo models of neurodegenerative and neurological disease, with a US office.

Neurodegenerative Models CNS Disease Models In Vitro Pharmacology In Vivo Efficacy Mouse Rat

SynAging

FR

French CRO focused on neurodegeneration and brain aging, offering in vivo models and readouts for Alzheimer's and related diseases.

Neurodegenerative Models Behavioral Assessment CNS Disease Models In Vivo Efficacy Mouse Rat

PsychoGenics

US

Preclinical CNS CRO offering behavioral pharmacology, translational neuroscience, EEG and disease models for psychiatric and neurological programs.

Neurodegenerative Models Behavioral Assessment CNS Disease Models Cognitive Testing EEG Studies Mouse Rat

Biospective

CA

Montreal-based neuroscience CRO combining neurodegenerative disease models with MRI imaging, quantitative neuropathology and image analysis.

Neurodegenerative Models CNS Disease Models Histopathology In Vivo Imaging MRI Studies Mouse Rat

The Jackson Laboratory (JAX In Vivo Services)

US

Nonprofit mouse genetics institute offering contract in vivo pharmacology using its own strains and humanized and PDX models across oncology, neuroscience, metabolism and immunology.

Neurodegenerative Models In Vivo Efficacy Metabolic Disease Models Oncology Models PDX Models Mouse

Scantox

DK GLP

GLP-accredited preclinical CRO headquartered in Denmark with sites in Sweden, Austria and the UK. Known for Gottingen minipig work and regulatory toxicology, with discovery pharmacology including CNS and…

Neurodegenerative Models CNS Disease Models Dermal Toxicity Formulation Development Genetic Toxicology Minipig Mouse Rabbit Rat

Questions to ask when choosing a Neurodegenerative Models CRO

  • Which models do you maintain in-house, and can you supply aged cohorts on our timeline?
  • What is the natural history of the model at your facility: onset, progression and variability of key endpoints?
  • Which behavioral and motor tests have you validated in this model, and are they scored blind?
  • Do you measure fluid biomarkers such as neurofilament light, and in which matrices?
  • For ASO or gene therapy programs, which CNS routes do you perform, and how is delivery confirmed?